Novavax, Inc. Aktie News

GAITHERSBURG, Md. , Oct. 30, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced it will report its third quarter 2025 financial results and operational highlights at 8:30 a.m.

Agreements signed to transfer one U.S.-based facility and sell certain equipment netting $60 million in cash and resulting in future cash savings of $230 million Novavax headquarters to remain in Gaithersburg, Md. GAITHERSBURG, Md.

Shah Capital has urged Novavax's board to pursue a sale of the biotech, citing a third consecutive year of poor roll-out of its COVID-19 shot, the hedge fund said on Tuesday.

GAITHERSBURG, Md. , Oct. 7, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) has completed the transfer of the marketing authorization for its COVID-19 vaccine, Nuvaxovid® to Sanofi, in the European Union (EU) enabling Sanofi to take full responsibility for commercial and regulatory activities in the EU.

GAITHERSBURG, Md. , Sept. 30, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced progress on its collaboration and license agreement (CLA) with Sanofi regarding Novavax's Matrix-M® adjuvant.

The reworked ACIP will make its debut Friday when the panelists weigh the suite of new Covid boosters from Pfizer, Moderna and Novavax.

Novavax, Inc. (NASDAQ:NVAX ) Cantor Global Healthcare Conference 2025 September 4, 2025 10:20 AM EDT Company Participants John Jacobs - President, CEO & Director Ruxandra Draghia-Akli - Executive VP and Head of Research & Development James Kelly - Executive VP, CFO & Treasurer Conference Call Participants Pete Stavropoulos - Cantor Presentation Pete Stavropoulos Welcome to the Cantor Global Hea...

GAITHERSBURG, Md. , Sept. 4, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced a milestone payment* from Takeda has been triggered by regulatory approval for Novavax's COVID-19 vaccine Nuvaxovid® Intramuscular Injection 1 mL formulated to target SARS-CoV-2 Omicron LP.8.1 as an initial immunization (first and second vaccination) for those aged six years or older and a booster imm...